Pediatrics · LP-015
Azithromycin Powder for oral suspension
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-015Pediatrics
- Generic identity
- AzithromycinPowder for oral suspension
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-015
- Generic identity
- Azithromycin
- Presentation
- Powder for oral suspension
- Catalogue strength
- 200 mg/5 mL
- Catalogue pack
- Bottle for reconstitution 15 mL / 30 mL
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: azithromycin.
- Dosage form: powder for oral suspension.
- Catalogue concentration: 200 mg/5 mL.
- Catalogue final-volume options: 15 mL and 30 mL.
Layer 02 · Unresolved product-specific fields
- Exact azithromycin salt/form basis and formula/excipients.
- Reconstitution water volume/steps, shaking and measuring-device instructions.
- After-reconstitution storage/discard period.
- Approved indication, age range, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 200 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution 15 mL | Reconstitution and after-opening/in-use instructions require the exact controlled product documentation. |
| B | 200 mg/5 mL | Powder for oral suspension | — | Bottle for reconstitution 30 mL | Reconstitution and after-opening/in-use instructions require the exact controlled product documentation. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Azithromycin is a macrolide antibiotic used for selected infections caused by susceptible bacteria. Tablet and oral suspension presentations support different administration needs, but neither makes the medicine appropriate for an undiagnosed respiratory illness. Antibiotic resistance and patient safety are important limits on use. This ingredient-level educational profile does not establish a Luang Pharma indication, registration, effectiveness claim or pediatric authorization.
Clinical context and therapeutic role
The clinical indication should be supported by assessment of the likely organism, local resistance and the role of alternative antibiotics. Respiratory, skin and other infections require condition-specific decisions rather than a generic broad-spectrum claim. Cardiac history and concurrent medicines are particularly relevant. When a liquid is selected for a child or a person with swallowing difficulty, the prescribed concentration, preparation instructions and measuring device must be confirmed.
Selected safety context
Azithromycin can affect cardiac repolarization and cause serious rhythm disturbances in susceptible patients, particularly with low potassium, a prolonged QT interval or interacting medicines. Liver injury, severe allergy and significant antibiotic-associated diarrhoea are additional concerns. Nausea, abdominal discomfort and diarrhoea may occur. Fainting, new palpitations, jaundice, breathing difficulty or blistering rash need urgent assessment. A clinician should reassess persistent symptoms rather than automatically repeat or extend antibiotic exposure.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
This presentation is a powder intended to become an oral suspension after product-specific reconstitution. The stated concentration should be interpreted using the registered label, including the final volume. Water volume, preparation method and excipients require confirmation; another product’s instructions cannot be used as a substitute.
Reconstitution should follow the exact supplied instructions and appropriate pharmacy practice. Record the relevant preparation information and use the correct oral measuring device. Check the authorized storage conditions and period after reconstitution; no universal refrigeration rule or discard interval is assumed.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and formula.
Approved label/leaflet with exact reconstitution/handling instructions.
Container/closure, measuring-device and packaging specification.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: AzithromycinArchived source classification: US National Library of Medicine medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
| NHS: About azithromycinArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 30 January 2026; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-015.
Professional enquiries
Request product-specific evidence for LP-015.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.